Silver Book Fact

Nearly 50% of diabetic retinopathy patients who received ranibizumab–an anti-VEGF drug–experienced substantial visual improvement after a year of injections

Bressler N, Chang T, Fine J, et al. Vision-Related Function after Ranibizumab Treatment by Better- or Worse-Seeing Eye: Clinical trial results from MARINA and ANCHOR. Ophthalmol. 2010; 117(4). http://www.aaojournal.org/article/S0161-6420(09)00981-6/abstract

Reference

Title
Vision-Related Function after Ranibizumab Treatment by Better- or Worse-Seeing Eye: Clinical trial results from MARINA and ANCHOR
Publication
Ophthalmol
Publication Date
2010
Authors
Bressler N, Chang T, Fine J, et al
Volume & Issue
Volume 117, Issue 4
Pages
747-56
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Treatments that have been found to delay or prevent diabetic retinopathy save the U.S. $1.6 billion annually.  
  • Intensive glucose control (3 or more daily insulin injections or continuous subcutaneous insulin infusion) reduced the mean risk of retinopathy progression by 54% in type 1 diabetes patients with minimal-to-moderate…  
  • Of the 8 million older Americans at high risk of developing advanced age-related macular degeneration (AMD), 1.3 million will develop advanced AMD within 5 years. However, the NEI-sponsored Age-Related Eye…  
  • Family risk of glaucoma
    “‘Five of my nine brothers and sisters had glaucoma,’ says 81-year-old Jean R. who for 20 years has depended on eye drops to decrease pressure inside her eyes. Jean is…  
  • Intensive Glycemic Control in People with Diabetes
    Intensive glycemic control in diabetics reduced their: Adjusted mean risk of DR by 76% Risk of progression by 54% Rates of laser surgery by 56% Risk of DME by 23%